ADE (cytarabine, daunorubicin, etoposide)
Checked 2026-09-09
Induction for younger adults with acute myeloid leukaemia in the UK MRC and NCRI trials; an alternative to 7+3
Also called ADE, ADE 10+3+5.
One cycle
every 28 days × 2 · about 8 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Cytarabine Pyrimidine nucleoside analogue (antimetabolite) | 100 mg/m² every 12 hours | IV | D1-10 | |
Daunorubicin Anthracycline (topoisomerase II inhibitor) | 50 mg/m² | IV | D1, 3, 5 | |
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative) | 100 mg/m² | IV | D1-5 |
Cycles
2 (course 1 as 10+3+5, course 2 as 8+3+5)
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- AML15 found no benefit from adding etoposide to daunorubicin and cytarabine (DA) in remission or survival, so DA or FLAG-Ida are now more often used.
- Gemtuzumab ozogamicin is added on day 1 for favourable and intermediate risk.
Used in
Products
Source
Burnett (MRC AML15), JCO 2013: ADE versus DA and FLAG-Ida
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
7+3 (cytarabine + anthracycline) ± midostaurin
Fit adults with newly diagnosed AML; midostaurin for FLT3-mutated disease (quizartinib for FLT3-ITD)
every 28 days × 1-2
Venetoclax + azacitidine
Newly diagnosed AML unfit for intensive chemotherapy
every 28 days
ATRA + arsenic trioxide
Low or intermediate-risk acute promyelocytic leukaemia (WBC 10 × 10⁹/L or less)
every 28 days